Epigallocatechin-3-Gallate Inhibits Stem-Like Inflammatory Breast Cancer Cells

Nora D. Mineva¹, K. Eric Paulson¹, Stephen P. Naber², Amy S. Yee³, Gail E. Sonenshein¹*

Introduction

Inflammatory Breast Cancer (IBC) is a highly aggressive form of cancer characterized by high rates of proliferation, lymphangiogenesis and metastasis, and an overall poor survival. As regular green tea consumption has been associated with improved prognosis of breast cancer patients, including decreased risk of recurrence, here the effects of the green tea polyphenol epigallocatechin-3-gallate (EGCG) were tested on two IBC lines: SUM-149 and SUM-190. EGCG decreased expression of genes that promote proliferation, migration, invasion, and survival. Consistently, growth, invasive properties, and survival of IBC cells were reduced by EGCG treatment. EGCG also reduced lymphangiogenesis-promoting genes, in particular VEGF-D. Conditioned media from EGCG-treated IBC cells displayed decreased VEGF-D secretion and reduced ability to promote lymphangiogenesis in vitro as measured by hTERT-HDLEC lymphatic endothelial cell migration and tube formation. Tumorsphere formation by SUM-149 cells was robustly inhibited by EGCG, suggesting effects on self-renewal ability. Stem-like SUM-149 cells with high aldehyde dehydrogenase (ALDH) activity, previously implicated in poor patient prognosis, were isolated. EGCG treatment reduced growth and induced apoptosis of the stem-like SUM-149 cells in culture. In an orthotopic mouse model, EGCG decreased growth of pre-existing tumors derived from ALDH-positive stem-like SUM-149 cells and their expression of VEGF-D, which correlated with a significant decrease in peritumoral lymphatic vessel density. Thus, EGCG inhibits the overall aggressive IBC phenotype. Reduction of the stem-like cell compartment by EGCG may explain the decreased risk of breast cancer recurrence among green tea drinkers. Recent clinical trials demonstrate the efficacy of green tea polyphenol extracts in treatment of prostate cancer and lymphocytic leukemia with low toxicity. Given the poor prognosis of IBC patients, our findings suggest further exploration of EGCG or green tea in combinatorial treatments against active IBC disease or in maintenance regimens to avoid recurrence is warranted.

Abstract

Inflammatory Breast Cancer (IBC) is a highly aggressive form of cancer characterized by high rates of proliferation, lymphangiogenesis and metastasis, and an overall poor survival. As regular green tea consumption has been associated with improved prognosis of breast cancer patients, including decreased risk of recurrence, here the effects of the green tea polyphenol epigallocatechin-3-gallate (EGCG) were tested on two IBC lines: SUM-149 and SUM-190. EGCG decreased expression of genes that promote proliferation, migration, invasion, and survival. Consistently, growth, invasive properties, and survival of IBC cells were reduced by EGCG treatment. EGCG also reduced lymphangiogenesis-promoting genes, in particular VEGF-D. Conditioned media from EGCG-treated IBC cells displayed decreased VEGF-D secretion and reduced ability to promote lymphangiogenesis in vitro as measured by hTERT-HDLEC lymphatic endothelial cell migration and tube formation. Tumorsphere formation by SUM-149 cells was robustly inhibited by EGCG, suggesting effects on self-renewal ability. Stem-like SUM-149 cells with high aldehyde dehydrogenase (ALDH) activity, previously implicated in poor patient prognosis, were isolated. EGCG treatment reduced growth and induced apoptosis of the stem-like SUM-149 cells in culture. In an orthotopic mouse model, EGCG decreased growth of pre-existing tumors derived from ALDH-positive stem-like SUM-149 cells and their expression of VEGF-D, which correlated with a significant decrease in peritumoral lymphatic vessel density. Thus, EGCG inhibits the overall aggressive IBC phenotype. Reduction of the stem-like cell compartment by EGCG may explain the decreased risk of breast cancer recurrence among green tea drinkers. Recent clinical trials demonstrate the efficacy of green tea polyphenol extracts in treatment of prostate cancer and lymphocytic leukemia with low toxicity. Given the poor prognosis of IBC patients, our findings suggest further exploration of EGCG or green tea in combinatorial treatments against active IBC disease or in maintenance regimens to avoid recurrence is warranted.

Citation: Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE (2013) Epigallocatechin-3-Gallate Inhibits Stem-Like Inflammatory Breast Cancer Cells. PLoS ONE 8(9): e73464. doi:10.1371/journal.pone.0073464

Editor: Seema Singh, University of South Alabama Mitchell Cancer Institute, United States of America

Received April 12, 2013; Accepted July 22, 2013; Published September 11, 2013

Copyright: © 2013 Mineva et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: These studies were supported by National Institutes of Health (NIH) grants R01 CA129129 and P01 ES011624 (G.E.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: gail.sonenshein@tufts.edu

Abstract

Inflammatory Breast Cancer (IBC) is a highly aggressive form of cancer characterized by high rates of proliferation, lymphangiogenesis and metastasis, and an overall poor survival. As regular green tea consumption has been associated with improved prognosis of breast cancer patients, including decreased risk of recurrence, here the effects of the green tea polyphenol epigallocatechin-3-gallate (EGCG) were tested on two IBC lines: SUM-149 and SUM-190. EGCG decreased expression of genes that promote proliferation, migration, invasion, and survival. Consistently, growth, invasive properties, and survival of IBC cells were reduced by EGCG treatment. EGCG also reduced lymphangiogenesis-promoting genes, in particular VEGF-D. Conditioned media from EGCG-treated IBC cells displayed decreased VEGF-D secretion and reduced ability to promote lymphangiogenesis in vitro as measured by hTERT-HDLEC lymphatic endothelial cell migration and tube formation. Tumorsphere formation by SUM-149 cells was robustly inhibited by EGCG, suggesting effects on self-renewal ability. Stem-like SUM-149 cells with high aldehyde dehydrogenase (ALDH) activity, previously implicated in poor patient prognosis, were isolated. EGCG treatment reduced growth and induced apoptosis of the stem-like SUM-149 cells in culture. In an orthotopic mouse model, EGCG decreased growth of pre-existing tumors derived from ALDH-positive stem-like SUM-149 cells and their expression of VEGF-D, which correlated with a significant decrease in peritumoral lymphatic vessel density. Thus, EGCG inhibits the overall aggressive IBC phenotype. Reduction of the stem-like cell compartment by EGCG may explain the decreased risk of breast cancer recurrence among green tea drinkers. Recent clinical trials demonstrate the efficacy of green tea polyphenol extracts in treatment of prostate cancer and lymphocytic leukemia with low toxicity. Given the poor prognosis of IBC patients, our findings suggest further exploration of EGCG or green tea in combinatorial treatments against active IBC disease or in maintenance regimens to avoid recurrence is warranted.
Materials and Methods

Ethics Statement
All animal procedures were conducted under an approved protocol #B2012-102 by the Tufts University Institutional Animal Care and Use Committee in accordance with the principals and procedures outlined in the NIH Guidelines for the Care and Use of Laboratory Animals. All surgery was performed under Isoflurane anesthesia and all efforts were made to minimize animal suffering.

Cell Culture and Treatment Conditions
SUM-149 and SUM-190 cells were isolated from primary inflammatory invasive ductal carcinoma by Stephen Ethier (University of Michigan Medical School, Ann Arbor, MI), who kindly provided the cells [22]. Upon receipt, cells were grown in Ham’s F-12 medium (Mediatech) containing 5% fetal bovine serum (FBS) (Invitrogen), 5 µg/ml insulin (Sigma), 1 µg/ml hydrocortisone (Sigma), 100 units/ml penicillin and 100 units/ml streptomycin (Hyclone). Cells were frozen immediately and fresh aliquots thawed and used approximately every 6 weeks. Studies were performed with cells within 6 passages. Cells were confirmed mycoplasma-free using a PCR-based test (VenoGeM Mycoplasma Detection Kit, Sigma). Cultures were treated with doses of EGCG (LKT Laboratories) of 5, 10, 20, 40, 60, 80 or 160 µg/ml which correspond to 10.9, 21.8, 43.6, 87.3, 130.9, 174.5 and 349.0 µM, respectively or with carrier DMSO equivalent to the highest dose of EGCG used (DMSO = 0 µM) to serve as DMSO controls.

Soft Agar and Matrigel Assays
For soft agar assays, 1.0×10^6 SUM-149 or 2.5×10^5 SUM-190 cells in a mix of 0.4% Bacto Agar (BD Biosciences) in complete media with the indicated doses of EGCG were plated on six-well plates and treated with the indicated doses of EGCG for 24 h. Following trypan blue exclusion, 5.0×10^5 unsorted SUM-149 cells or sorted ALDH-positive SUM-149 cells were plated in triplicate in 96-well tissue culture treated or low attachment plates, respectively. Following treatment with the indicated doses of EGCG for 24 h, supernatants and cells (trypsinized and syringed to a single cell suspension) were exposed to 0.4% trypan blue. The average percent of dead cells was calculated as the number of trypan blue positive cells divided by the total number of cells multiplied by 100± SD. Data are shown from a representative of three independent experiments. Caspase-3 and -7 activities were assessed using a Caspase-Glo 3/7 Luminescent Assay (Promega). Briefly, 2.5×10^4 ALDH-positive SUM-149 cells were plated in triplicate in 96-well tissue culture treated or low attachment plates and treated with the indicated doses of EGCG for 24 h. Luminescence was measured and values normalized to cell viability (ATP levels from similarly treated samples). Values shown are average fold changes (relative to control set to 1) ± SD of three independent experiments combined.

RT-PCR
RNA was isolated from cells in culture or frozen tumor tissue and cDNA prepared as described [24]. Expression of CCND1, RHOC, FNU, CDH1, VIM, BCL-XXL, VEGF-A, VEGF-B, VEGF-C, VEGF-D, NANOG, STELLA, control GADPH and 18S rRNA was assessed by reverse transcription (RT)-PCR using the thermal cycler conditions and primer sets detailed in Materials S1. Resulting PCR products were subjected to gel electrophoresis and densitometry. Expression levels, normalized to GAPDH or 18S rRNA, are given as fold change relative to experimental control sample set to 1.0 from 3 independent experiments.

Cell Growth and Survival Analyses
As a measure of cellular metabolism and therefore growth and viability, ATP levels were assessed in 3.0×10^5 SUM-149 cells and 4.0×10^5 SUM-190 cells using an ATPlite luminescence ATP detection assay system (Perkin Elmer), as described previously [24]. For comparison of ATP levels in the total SUM-149 cell population vs sorted ALDH-positive SUM-149 cells, 1.25×10^5 cells were used. Average ATP levels, for triplicate samples, are presented as percent of controls ± Standard Deviation (SD). For evaluation of cellular DNA content, cells were treated with the indicated doses of EGCG for 72 h, stained with PI and analyzed by FACS, as previously described [25]. Data (5,000 events) were collected on a linear scale to assess DNA content and analyzed using WinMDI software. For soft agar assays, 1.0×10^5 SUM-149 or 2.5×10^5 SUM-190 cells in a mix of 0.4% Bacto Agar (BD Biosciences) in complete media with the indicated doses of EGCG were plated on six-well
dishes pre-coated with a 1:1 mix of 2×Ham’s F-12 medium supplemented with 10% FBS and 1.6% Bacto Agar. Cells were fed 3 times/week with complete Ham’s F-12 medium containing DMEM or the indicated dose of EGCG. After 3 weeks, cells were stained overnight with 0.2 mg/ml iodonitrotetrazolium chloride (Sigma) and photographed at 40×magnification. Colonies with diameters of approximately 20 microns or greater were counted using ImageJ software (NIH). Matrigel assays were carried out as described previously [26] using single cell suspensions of 5.0 × 10^3 SUM-149 cells or 7.5 × 10^3 SUM-190 cells with Ham’s F-12 media containing 0 or 40 μg/ml EGCG. Cultures were incubated for 10 days or 14 days for SUM-149 and SUM-190, respectively and photographed.

**Immunoblot Analysis**

Whole cell extracts from cells in culture or frozen homogenized tumor tissue were prepared and immunoblotted as previously described [27]. Antibodies against cleaved Caspase-3 (#9661) and cleaved PARP (#9501-9000017) were from Cell Signaling and BD Biosciences, respectively. Mouse monoclonal anti-human VEGF-D (MAB222) and β-actin antibodies were from R&D Systems and Sigma, respectively. To detect secreted VEGF-D protein, concentrated conditioned media corresponding to 1.0 × 10^6 IBC cells/condition were used in immunoblotting.

**Wound Healing Assays**

 Cultures of hTERT-HDLEC cells at 95% confluence were scratched with a sterile 200 μl micropipette tip, washed with 1× PBS and exposed to EBM-2 Basal Medium (Lonza) supplemented with 1% FBS and concentrated conditioned Ham’s F-12 medium (corresponding to 1.0 × 10^6 SUM-149 or 1.5 × 10^6 SUM-190 cells treated with DMSO or EGCG for 24 h). Alternatively, Ham’s F-12 medium incubated with either DMSO or EGCG in the absence of IBC cells was concentrated and used. The same fields of the wound margin were photographed at 100×magnification at 0 and 24 h. Wound areas were determined using ImageJ software. Values for percent wound closure were calculated for each condition by subtracting the remaining (unclosed) wound area at 24 h from the wounded area at 0 h (set to 100%). Values shown are averages of triplicate samples ± SD.

**Tube Formation Assays**

Tube formation assays were performed as described [28]. hTERT-HDLEC (1.5 × 10^5) cells were plated, in triplicate, on glass chambers coated with growth factor reduced Matrigel (BD Biosciences). Cells were incubated in 200 μl EBM-2 Basal Medium supplemented with 1% FBS and concentrated conditioned medium from DMSO- or EGCG-treated SUM-149 or SUM-190 cells (volume corresponding to 0.65 × 10^6 or 1.0 × 10^6 cells, respectively). Alternatively, concentrated DMSO- or EGCG-treated control Ham’s F-12 medium (no IBC cells) was added. Following incubation for 15 h, three random fields/well were photographed (40×magnification). Incomplete networks were excluded and numbers of closed networks of vessel-like tubes counted in 3 fields (n = 9). The average percentage relative to control samples is presented ± SD.

**VEGF-D Immunodepletion**

VEGF-D was immunodepleted from conditioned concentrated medium from untreated SUM-149 or SUM-190 cells using a rabbit anti-VEGF-D antibody (sc-25784) or control normal rabbit IgG (sc-2027) [both from Santa Cruz Biotechnology] bound to rec-Protein G-Sepharose 4B beads (Invitrogen), or alternatively crosslinked with bis(sulfosuccinimidyl) suberate (Thermo Scientific) to Protein G Dynabeads (Invitrogen) as recommended by the manufacturer. Immunodepleted medium was used in wound healing or tube formation assays or immunoblotted for VEGF-D.

**Tumorsphere Formation Assay**

Single cell suspensions of 2.0 × 10^5 SUM-149 cells in complete Ham’s F-12 medium containing the indicated concentrations of EGCG were plated, in triplicate, on low attachment six-well dishes. After 7 days of culture, primary spheres were photographed at 200×magnification and those with diameters of ~125 microns or greater counted manually using the objective ruler. Primary spheres in control DMSO treated group were then collected by centrifugation, digested using Accutase (Invitrogen) and 5 × 10^3 single cells subcultured for secondary sphere formation in the presence of EGCG. For tertiary sphere formation, 10^3 cells obtained from DMSO-treated, digested secondary spheres were used. Culture conditions and analysis of secondary and tertiary spheroids was performed as for primary spheres. Sphere forming efficiency was calculated as number of spheres formed/total number of cells plated/100. Values shown are averages ± SD of three independent experiments combined.

**Xenograft Mouse Model**

Six-week-old female nonobese diabetic/severe combined immuno deficiencies (NOD/SCID) mice (Jackson Laboratory) were implanted with 5.0 × 10^3 sorted ALDH-positive SUM-149 cells in a 30 μl 50% Matrigel (BD Biosciences, CB-10230A) solution (1:1 dilution of Matrigel with Ham’s F-12 medium) in the fourth inguinal mammary fat pad. Once palpable tumors were detected, mice were separated into two groups (n = 6), weighed, and administered a 0.1 ml intraperitoneal injection of 16.5 mg/kg EGCG (Sigma, E4143) or control PBS five times a week for the first five weeks and daily for the last week. Tumor size was measured with calipers twice a week and tumor volumes were calculated using the formula: [length × width^2]/2. Mice were given autoclaved food and water ad libitum until sacrifice. Tumors were dissected, weighed, sectioned and snap frozen in liquid nitrogen for RNA and protein isolation or fixed in 10% Neutral buffered Formalin for histological analysis.

**Immunohistochemistry and Evaluation of Lymphatic Vessel Density**

For evaluation of lymphatic vessel density, fixed tumor tissues were paraffin embedded and 4-μm-thick sections prepared using standard procedures at the Tufts University Division of Laboratory Animal Medicine Histology Core. For each mouse, 4 slides/tumor were cut 200 μm apart and subjected to immunostaining for podoplanin. Briefly, tumor sections were deparaffinized, rehydrated through a descending ethanol gradient and subjected to heat-induced antigen retrieval. Sections were blocked with Renaissance Background Reducing Diluent (Biocare Medical) at a dilution of 1:500 overnight at 4°C. Slides were stained using a BenchMark XT instrument (Ventana Medical Systems) at the Tufts Medical Center Department of Pathology and Laboratory Medicine. Slides were examined at low magnification and three areas with the greatest numbers of vessels (hot spots) at the tumor periphery/peritumoral area (defined as a 2-mm-wide band containing the invasive front) were identified for each tumor slice. These were photographed at 400×magnification and the numbers of vessels/hotspot counted and the average value.
of Vessel Density/slide plotted. If no hot spots were detected, these tumor sections were given a zero count. One tumor section from the Control group displayed less than 5% peripheral tumor tissue and was excluded from analysis. Thus, we compared n = 24 for the EGCG-treated and n = 23 for the Control group.

Statistical Analysis
Statistical significance between samples was determined using a one-way ANOVA with a Tukey HSD post hoc test for wound healing and tube formation assays using conditioned media from IBC cells treated with EGCG or DMSO, or control conditioned media. All other analyses were performed using a two-tailed Student’s t-test for samples with equal variance.

Results
EGCG Inhibits Expression of Genes that Promote Growth, Transformed Phenotype and Survival of IBC Cells
As an initial test of the effects of EGCG on IBC cells, a preliminary dose-response curve was performed on SUM-149 and SUM-190 cells and a concentration of 40 µg/ml EGCG selected, which inhibited growth of both lines by ~50% (not shown and see Fig. 1C). Using this dose, the effects of EGCG on RNA expression of genes that control proliferation, migration, invasion, and survival were examined (Fig. 1A). The data from this and two additional independent experiments were quantified, normalized to the GAPDH control and averaged ± SD presented in Figure 1B. EGCG substantially decreased mRNA levels of CCND1, encoding the proliferation marker Cyclin D1, RHOC and FN1 in both lines; although the decrease in FN1 did not reach statistical significance for SUM-190 cells. RhoC and fibronectin have been implicated in IBC signaling and breast cancer cell migration [10,11,29]. IBC cells typically overexpress E-cadherin, which promotes their ability to form emboli [8,9]. EGCG reduced RNA levels of CDH1, encoding E-cadherin, in SUM-199 but not in SUM-190 cells. RNA expression of the mesenchymal marker VIM was reduced by EGCG in SUM-149 cells, but was not detectable in SUM-190 cells (Fig. 1A). Lastly, EGCG reduced expression of the pro-survival BCL-2 XL gene in both lines. Thus, EGCG inhibits the expression of genes that promote IBC cell growth, transformed phenotype and survival, and these properties are explored below.

EGCG Reduces IBC Cell Growth, Invasive Phenotype and Survival
As a measure of cellular metabolism and therefore growth and viability, ATP levels were assessed. EGCG treatment caused a robust, dose-dependent decrease in ATP levels in SUM-149 and SUM-190 cells (Fig. 1C), which was more profound in SUM-149 cells at the higher doses. To study anchorage-independent growth, cells were grown in soft agar (Fig. 1D). The number of SUM-149 colonies formed was significantly decreased with EGCG in a dose-dependent manner. SUM-190 colony numbers were only decreased at 160 µg/ml EGCG. We next examined invasive outgrowth in Matrigel (Fig. 1E and 1F). Both SUM-149 and SUM-190 cells formed spheres, which resembled tumor emboli typically seen infiltrating the dermal lymphatic channels of IBC patients [8]. Within 10 days of culturing, SUM-149 cells formed large multi-focal 3D spheroids with “grape-like” morphology [30]. Treatment with 40 µg/ml EGCG robustly reduced the size and invasive characteristics of these spheroids (Fig. 1E). SUM-190 cells required a somewhat longer incubation time (14 days) to form similarly sized spheres, which had a round outline, resembling “mass” morphology [30] (Fig. 1F). EGCG treatment resulted in a substantial reduction in the size of SUM-190 spheres.

To test whether EGCG induces apoptosis, DNA content was quantified by FACS analysis. A substantial increase in the percentage of cells with a sub-2N DNA content was detected in SUM-149 cells with 80 µg/ml EGCG (Fig. 2A), and no viable cells remained with 160 µg/ml EGCG (data not shown). SUM-190 cells were more resistant, and a significant extent of cell death was seen only at 160 µg/ml EGCG (Fig. 2B). Results from three independent experiments confirm that ~30% of SUM-199 cells undergo apoptosis at 80 µg/ml EGCG, whereas a higher EGCG concentration of 160 µg/ml is needed to see the same extent of SUM-190 cell death (Fig. 2C). Cleavage of Caspase-3 and PARP proteins was also monitored. Consistently, levels of cleaved Caspase-3 and PARP were significantly elevated in SUM-149 and SUM-190 cells at 80 and 160 µg/ml of EGCG, respectively (Fig. 2D). In summary, EGCG causes a dose-dependent decrease in growth of SUM-149 and SUM-190 IBC cells at lower concentrations and at higher doses induces apoptosis. The ability of the IBC cells to form spheres in Matrigel is also greatly reduced by EGCG treatment.

EGCG Treatment of IBC Cells Reduces Secretion of Factors that Stimulate In vitro Lymphangiogenesis
Since growth and dissemination of IBC tumors require angiogenesis and lymphangiogenesis, which are mediated by VEGF family members VEGF-A, VEGF-B, VEGF-C, and VEGF-D [31], the effects of EGCG on RNA expression of these genes was assessed next (Fig. 3A and 3B). EGCG treatment of SUM-149 cells significantly decreased VEGF-A, VEGF-C and VEGF-D RNA levels while VEGF-B expression was unaffected. In SUM-190 cells, only a decrease in VEGF-D levels was seen with EGCG. Notably, VEGF-D is significantly elevated in primary IBC samples compared to non-IBC tumors [12], and implicated in promoting tumor dissemination by lymphangiogenesis [31]. The ability of IBC cells to secrete factors that stimulate lymphangiogenesis, and the effects of EGCG were next assessed by using lymphatic endothelial cell migration and tube formation assays. Serum-free medium was used to avoid FBS, which clogs the filters used for concentration. This permits lowering the EGCG dose to 10 µg/ml as the polyphenol is more stable in the absence of serum factors. Conditioned serum-free media from untreated and EGCG-treated IBC cells or from plates without cells were collected and concentrated. Media without cells showed no effects on hTERT-HDLEC cell migration (Figs. 3C and 3D, 4A and 4B) or survival (data not shown), suggesting EGCG had no direct effects on these cells. Addition of concentrated conditioned medium from DMSO-treated SUM-149 cells (Fig. 3C and 3D) or SUM-190 cells (Fig. 4A and 4B) led to statistically significant increases in wound closure at 24 h. EGCG treatment of SUM-149 or SUM-190 cells prevented this increase, such that percent wound closure was equal to that seen with control media (Fig. 3C and 3D and Fig. 4A and 4B). Thus, secretion of factors by IBC cells that promote migration of hTERT-HDLEC cells is inhibited by EGCG.

We next assessed the effects of conditioned media on tube formation by hTERT-HDLEC cells. Compared to control media, a greater number of closed networks of vessel-like tubes was seen when hTERT-HDLEC cells were incubated with media from SUM-149 (Fig. 3E) or SUM-190 cells (Fig. 4C). Quantification of the images indicated that the differences were significant for both cell lines (Figs. 3F and 4D). Stimulation of tube formation by media from SUM-149 (Fig. 3E and 3F) or SUM-190 (Fig. 4C and 4D) cells was prevented by EGCG; whereas, addition of media containing EGCG incubated in the absence of cells had no effect on the number of tubes formed. Thus, IBC cells secrete factors...
Figure 1. EGCG alters gene expression, growth and invasive phenotype of IBC cells. (A–B) RNA analysis. SUM-149 (left panels) and SUM-190 cells (right panels) were treated with 40 μg/ml EGCG or equivalent volume of carrier DMSO (0 μg/ml EGCG) for 72 h. RNA was analyzed by RT-PCR for levels of Cyclin D1 (CCND1), RHOC, Fibronectin (FN1), E-cadherin (CDH1), Vimentin (VIM) and BCL-XL and representative images shown (A). Values for RNA expression were obtained from 3 independent experiments by densitometry and normalization to the loading control GAPDH, and are given as average fold changes ± SD relative to experimental control sample set to 1.0. (B). *, p-value <0.05; **, p-value <0.005. (C) ATP levels. SUM-149 (left panel) and SUM-190 cells (right panel) were treated, in triplicate, with the indicated doses of EGCG for 72 h. ATP levels were measured and analyzed as described in Materials and Methods. *, p-value <0.05 and **, p-value <0.005 for comparison of individual EGCG doses to control untreated sample. (D) Anchorage independent growth. SUM-149 (left panel) and SUM-190 cells (right panel) were subjected to a soft agar colony
that stimulate endothelial cell tube formation and EGCG treatment inhibits these effects.

**VEGF-D Secretion by IBC Cells Promotes Lymphatic Endothelial Cell Migration and Tube Formation**

VEGF-D has the ability to promote lymphangiogenesis [31]. Given our data showing the green tea polyphenol reduces VEGF-D RNA levels, the effects of EGCG on VEGF-D secretion were examined. Cells were incubated with 0, 5 or 10 μg/ml EGCG and VEGF-D levels in the conditioned concentrated media measured. EGCG robustly reduced secretion of VEGF-D protein from both IBC lines (Fig. 5A). To directly test the role of VEGF-D secretion in lymphangiogenic properties of IBC cells, conditioned medium from untreated cells was immunodepleted with an anti-VEGF-D antibody or normal IgG, as a control and then used in wound healing and tube formation assays. Following immunodepletion, VEGF-D levels were decreased by ~45% and 27% in SUM-149 and SUM-190 media, respectively (Fig. 5B); whereas, levels of VEGF-A and VEGF-C were unaffected (Figure S1), confirming the specificity of the antibody. VEGF-D depletion significantly decreased the ability of SUM-149 and SUM-190 conditioned media to stimulate wound closure by hTERT-HDLEC cells (Fig. 5C). To assess the role of VEGF-D in tube formation assays, we first tested the effects of addition of 50 ng/ml recombinant

![Figure 2](image-url)
Figure 3. EGCG prevents stimulation of lymphatic endothelial cell migration and tube formation by SUM-149 cells. (A–B) RNA analysis. SUM-149 (left panels) and SUM-190 cells (right panels) were treated with 40 μg/ml EGCG or DMSO (0 μg/ml EGCG) for 72 h. RNA was analyzed by RT-PCR for levels of VEGF-A, VEGF-B, VEGF-C, VEGF-D and GAPDH. (A) Images from a representative experiment are shown. (B) Values for RNA expression from three independent experiments were normalized to the loading control GAPDH and are given as average fold change ± SD.
EGCG Inhibits Inflammatory Breast Cancer Cells

relative to the experimental control samples set to 1.0. *, p-value <0.05; **, p-value <0.005. (C–D) Wound healing assays. Scratched hTERT-HDLEC cultures were exposed to EBM-2 Basal Medium plus 1% FBS and supplemented with concentrated Ham’s F-12 medium from SUM-149 cells treated with DMSO (0 μg/ml EGCG) (SUM-149+ DMSO) or 10 μg/ml EGCG (SUM-149+ EGCG) corresponding to equal cell numbers/condition. Alternatively, similarly treated concentrated conditioned Ham’s F-12 medium from plates without cells was used (Control [Ctrl] medium). Wound scratches were photographed and analyzed as described in Materials and Methods. White lines indicate the position of the original scratch. Representative images are shown (C). Percent wound closure values represent averages of triplicate samples ± SD (D). *, p-value <0.05; **, p-value <0.005. (E–F) Tube formation assays. hTERT-HDLEC cells were subjected to tube formation assays as described in Materials and Methods using EBM-2 Medium supplemented as in part C. Representative images are shown (E). Values for closed networks are given as averages of nine fields ± SD (F). **, p-value <0.005.

doi:10.1371/journal.pone.0073464.g003

human VEGF-D protein. VEGF-D addition resulted in an increase in hTERT-HDLEC tube formation of ~29% (data not shown). Consistently, VEGF-D depletion in SUM-149 and SUM-190 cell conditioned media led to substantially reduced numbers of closed networks of vessel-like tubes (Fig. 5D). Thus, secretion of VEGF-D by IBC cells, which stimulates lymphatic endothelial cell migration and tube formation, is strongly inhibited by EGCG.

EGCG Inhibits Stem-like SUM-149 Cells in Culture

Wicha and coworkers have demonstrated the presence of a cancer stem-like cell population in the SUM-149 but not the

Figure 4. EGCG prevents stimulation of lymphatic endothelial cell migration and tube formation by SUM-190 cells. (A–B) Wound healing assays of the effects of EGCG on secretion of factors by SUM-190 cells were performed as described above for SUM-149 cells in Fig. 3C and 3D. White lines indicate the position of the original scratch. Representative images are shown (A). Percent wound closure values shown are averages of triplicate samples ± SD (B). *, p-value <0.05; **, p-value <0.005. (C–D) hTERT-HDLEC cells were subjected to tube formation assays with SUM-190 cell conditioned media as in Fig. 3E and 3F. Representative images are shown (C). Values for closed networks are given as averages of nine fields ± SD (D). **, p-value <0.005.

doi:10.1371/journal.pone.0073464.g004
SUM-190 cell line [32]. As an initial test of the effects of EGCG on SUM-149 cell self-renewal capacity, an in vitro tumorsphere assay was performed under low attachment conditions with serial passage (Fig. 6A). Primary SUM-149 tumorsphere formation was potently decreased with 40 μg/ml EGCG and 80 μg/ml EGCG completely inhibited their formation. Dissociation of primary spheres and passage onto secondary and subsequent tertiary spheres led to an increase in sphere forming efficiency at each step consistent with enrichment of cells with self-renewal capacity (Fig. 6B). Notably, formation of secondary and tertiary spheres was almost completely inhibited in the presence of EGCG even at the lower dose of 40 μg/ml (Fig. 6A and 6B).

To specifically test the effects of EGCG on the stem-like cell compartment, ALDH-positive SUM-149 cells were isolated using a FACS-based ALDEFLUOR assay. As noted above, SUM-190 cells are ALDH-negative [32] (data not shown). The SUM-149 cell population contained 9.6±1.1% ALDH-positive cells as judged by comparison to a sample with the ALDH inhibitor DAB (Fig. 6C, R1 gate). The dimmest 10% of the total population was designated ALDH-negative (Fig. 6C, R2 gate). Consistent with isolation of a stem-like cell compartment, increased expression of pluripotent stem cell markers MVIQ and STELLA was observed in ALDH-positive SUM-149 cells as compared to ALDH-negative ones (Fig. 6D). EGCG treatment of SUM-149 ALDH-positive cells led to a significant dose-dependent decrease in ATP levels, although it was more moderate than that seen for the total SUM-149 cell population (Fig. 6E). Treatment of ALDH-positive SUM-149 cells with the higher EGCG doses (80 and 160 μg/ml) induced cell death (Fig. 6F and 6G); although again to a lesser extent than seen for the total population. These findings are consistent with the notion that the ALDH-negative cells, which represent ~90% of the total population, are more sensitive to EGCG. ALDH-positive breast cancer cells have been reported to localize to tumor regions with increased microvesSEL density [33], suggesting potential paracrine interactions with endothelial cells. Thus, we next examined the expression of VEGF family members in ALDH-positive vs ALDH-negative SUM-149 cells. Interestingly, RT-PCR analyses revealed that VEGF-D expression was substantially higher in ALDH-positive vs ALDH-negative cells, whereas both populations had similar levels of VEGF-A, VEGF-B, and VEGF-C RNA (Fig. 6H). Since EGCG treatment reduced the levels of VEGF-A, VEGF-C and VEGF-D in the total SUM-149 cell population, we next assessed the expression of these factors following polyphenol treatment of the purified ALDH-positive cells. Notably, EGCG reduced the levels of VEGF-D RNA by ~50%, while no change was seen in VEGF-A or VEGF-C RNA levels (Fig. 6I). Thus, EGCG reduces the self-renewal capacity of SUM-149 cells and the growth, VEGF-D expression and survival of the ALDH-positive stem-like subpopulation.

**EGCG Reduces Growth of Pre-existing Tumors Derived from SUM-149 Stem-like Cells**

To investigate the effects of EGCG on growth of pre-established IBC tumors, ALDH-positive SUM-149 cells were injected into the mammary fat pad of female mice. After 25 days, palpable tumors were detected in all of the mice. Treatment was initiated the next day (day 1) with 16.5 mg/kg EGCG or control PBS 5 days a week. A statistically significant decrease in tumor size was detected in EGCG vs control populations at day 32 (Fig. 7A). As we noted a loss of significance at day 36 following a weekend hiatus in treatment, we extended the treatment period to 5 weeks. As shown in Fig. 7B, 5 days of EGCG treatment significantly reduced tumor burden. As previously reported, tumors developed in all control animals while animals treated with EGCG showed a variable extent of tumor regression.
Figure 6. EGCG reduces viability and VEGF-D expression of IBC stem-like cells in vitro. (A–B) SUM-149 cells were subjected to primary (1\textsuperscript{st}), secondary (2\textsuperscript{nd}) and tertiary (3\textsuperscript{rd}) tumoursphere formation assays under low attachment conditions in the absence or presence of EGCG. After 7 days of culture, spheres with a diameter $\geq 125\ \mu m$ or greater were counted. Representative images are shown (A). Sphere forming efficiency was calculated as number of spheres formed/total number of cells plated $\times 100$. Values given represent averages $\pm$ SD from three independent experiments (B). Scale bar = 125 $\mu m$. **, p-value $< 0.005$ for comparison to control untreated sample or as indicated. (C) ALDH activity. SUM-149 cells were subjected to a FACS-based ALDEFLUOR assay. Left and right panels: scatter plots of cells incubated with ALDH substrate in the presence or absence of the ALDH inhibitor DEAB, respectively. R1- ALDH-positive cells; R2- ALDH-negative cells. Percent ALDH-positive cells represents average of three experiments $\pm$ SD. (D) RNA from ALDH-positive vs -negative cells was analyzed by RT-PCR and a representative of two independent experiments shown. Values $\pm$ Standard Error (SE) are given below for fold change relative to ALDH-negative sample set to 1.0. (E–G) Unsorted SUM-149 cells (white bars) or sorted ALDH-positive SUM-149 cells (black bars) were treated with EGCG for 24 h. ATP levels (E) and percent dead cells (F) were determined as described in Materials and Methods. **, p-value $< 0.005$. (G) Caspase-3/7 activity was measured in ALDH-positive cells using a Caspase-Glo 3/7 assay. *, p-value $< 0.05$; **, p-value $< 0.005$. (H–I) RT-PCR analysis was performed for VEGF family members in ALDH-positive vs -negative cells (H) and in ALDH-positive cells treated with EGCG for 24 h (I). A representative experiment in each case is shown. Expression values represent average fold change of three independent experiments $\pm$ SD relative to control samples set to 1.0.

doi:10.1371/journal.pone.0073464.g006
EGCG Inhibits Inflammatory Breast Cancer Cells

Discussion

Here, EGCG is shown for the first time to inhibit the growth and lymphangiogenic potential of pre-existing tumors derived from SUM-149 IBC ALDH-positive stem-like cells in an orthotopic mouse model. Consistently, treatment of SUM-149 IBC stem-like cells or total populations of SUM-149 and SUM-190 IBC cells in culture with the green tea polyphenol caused a dose-dependent inhibition of cell growth and transformed phenotype at lower concentrations and induced apoptosis at higher doses. EGCG treatment also decreased VEGF-D expression in tumors, SUM-149 stem-like cells and in the total populations of SUM-149 and SUM-190 cells, consistent with observed suppression of the ability of the SUM-149 and SUM-190 IBC cells to stimulate in vitro lymphatic endothelial cell migration and tube formation. Furthermore, EGCG robustly inhibited formation of tumorspheres by SUM-149 cells, suggesting this polyphenol can reduce the capacity for self-renewal. Regular green tea consumption prior to breast cancer diagnosis has been associated with decreased subsequent risk of recurrence [20]. Our findings suggest that repression of the cancer stem-like cell compartment by green tea polyphenols could play an important role. Given the poor prognosis of IBC patients and our findings demonstrating pleiotropic inhibitory effects of EGCG on this aggressive form of breast cancer, the use of EGCG or green tea in combination with standard treatment modalities for IBC patients warrants further exploration.

Several recent clinical trials for prostate cancer and lymphocytic leukemia using various green tea polyphenol extracts have shown efficacy with low toxicity. Short-term daily supplementation with Polyphenon E, a decaffeinated green tea polyphenol preparation (containing 800 mg of EGCG), in prostate cancer patients during the time between prostate biopsy and radical prostatectomy decreased cancer associated markers HGF, VEGF-A and PSA [35]. Only 3% of patients with high grade prostatic intraepithelial neoplasia given capsules of green tea extracts for one year progressed to prostate cancer compared to 30% in the placebo group [36]. A two-year follow-up demonstrated that this was a long-lasting effect [37]. Polyphenon E with daily EGCG doses ranging from 800 to 4000 mg for 6 months, corresponding to a maximum dose of ~35 mg/kg for women, to previously untreated chronic lymphocytic leukemia patients with Rai stage 0 to II disease resulted in a significant reduction in absolute lymphocyte count and lymphadenopathy [38]. Polyphenon E and EGCG in ointment or capsules were protective in patients with human papilloma virus-infected cervical lesions [39]. Notably, the EGCG dose used in mice in the present study (16.5 mg/kg) was comparable to the well-tolerated doses given to cancer patients.

The human ALDH superfamily of NAD(P)_H-dependent enzymes promotes oxidation of toxic aldehydes into weaker carboxylic acids [40]. High expression of different ALDH family members or total ALDH enzymatic activity are now used to isolate cancer stem-like cells from a variety of solid tumors [40]. ALDH1 expression in particular has been associated with resistance to therapy and a tendency towards disease relapse in breast cancer patients [41,42]. Previous studies have characterized SUM-149 cells with high ALDH enzymatic activity as an aggressive subpopulation with cancer stem-like cell properties, including self-renewal capacity and high tumorigenicity, and found to mediate invasion in vitro and metastasis in mice [16]. Notably in IBC patients, the presence of ALDH1-expressing stem-like cells has been correlated with development of early metastasis and decreased patient survival [16]. EGCG reduced ALDH-positive SUM-149 stem-like cell proliferation in vitro and growth of tumors derived from this stem-like cell compartment. This more highly aggressive subpopulation of the SUM-149 cell line was selected in our study to provide a more stringent test of the efficacy of the green tea polyphenol; although, we cannot exclude the possibility that other highly aggressive subpopulations exist within SUM-149 cultures that may not be affected by EGCG. In previous work green tea polyphenols were found to reduce mammosphere formation and stem-like cells in culture. For example, the increase in mammospheres and percent ALDH-positive cells within these structures resulting from carcinogen treatment of untransformed MCF10A cells was blocked by EGCG [43]. Similarly, EGCG derivatives reduced the percent CD44+/CD24− cancer stem-like cells in MDA-MB-231 cell cultures and their ability to form mammospheres [44]. To our knowledge, this is the first report demonstrating the efficacy of EGCG in an in vitro model against tumors derived from stem-like breast cancer cells.

Interestingly, IBC cells were capable of stimulating endothelial cell function through the secretion of soluble factors, as judged by lymphatic endothelial cell migration and tube formation assays. EGCG treatment reduced IBC cell secretion of VEGF-D, a major regulator of tumor associated lymphangiogenesis, and thereby their ability to stimulate endothelial cell function in vitro. Van der Auwera and colleagues report no significant difference in lymphatic vessel parameters (vessel number, vessel perimeter and area covered) at intratumoral or peritumoral areas of IBC tumors [45]. Since our tumors had highly necrotic centers, we chose to assess peri- or peritumoral lymph vessels as a representative measurement. EGCG profoundly decreased lymphatic vessel recruitment toward the tumor periphery in mice. Our studies implicate VEGF-D in these paracrine interactions between IBC cells and endothelial cells in the tumor microenvironment. Immunodepletion of VEGFD from IBC cell media resulted in decreased stimulation of lymphatic endothelial cell migration and tube formation. VEGFD−/− mice showed decreased peritumoral lymphangiogenesis and lymph node metastasis in an orthotopic pancreatic tumor model [46]. Inhibition of VEGF-D in a mammary fat pad xenograft model with a specific antibody prevented lymphangiogenesis and metastasis [14]. In patients with invasive breast cancer, VEGF-D expression in tumor cells correlated with increased lymphatic vessel density, lymph node metastasis and decreased disease-free survival [47,48]. VEGF-D expression is significantly...
Figure 7. EGCG treatment inhibits growth and lymphangiogenic potential of tumors derived from ALDH-positive cells in mice. (A) Female NOD/SCID mice were implanted with SUM-149 ALDH-positive cells in the 4th inguinal mammary fat pad (MFP injection) and separated into two groups (n = 6/group) once tumors became palpable (Tumors detected). Mice were treated by intraperitoneal injection with 16.5 mg/kg EGCG or Control 1X PBS (Treatment start). Tumor size was measured with calipers twice a week and tumor volumes calculated. Values shown are averages per group ± SE. *, p-value < 0.05; **, p-value < 0.005. (B) Following sacrifice, tumors were dissected out and weighed. Values shown are averages per group ± SE. *, p-value < 0.05. (C–D) Tumor RNA was isolated and analyzed by RT-PCR using primers specific for human VEGF-D and for 18S rRNA (C). Levels of hVEGF-D normalized to 18S rRNA for each mouse per group are presented. Solid line represents median of the group (D). **, p-value < 0.005. (E–F) Tumor proteins were extracted and separated by gel electrophoresis. Proteins were stained with Ponceau red and subjected to Western blotting for VEGF-D (E). Values of VEGF-D normalized to total Ponceau staining per sample are presented for each mouse per group. Solid line represents median of the group (F). *, p-value < 0.05. (G–H) Tumor sections from Control or EGCG-treated mice were stained with an anti-podoplanin antibody.
EGCG Inhibits Inflammatory Breast Cancer Cells

Representative images at 400× are shown (G). P-peritumoral area; T-tumor. Immunostained sections were analyzed and lymphatic vessel density quantified as described in Materials and Methods (H). Lymphatic vessel density for the Control and EGCG-treated groups is given as the average number of vessels in 3 hot spots in each of 4 podoplanin stained tumor sections per mouse. Solid line represents median of the group. **, p-value <0.005.

doi:10.1371/journal.pone.0073464.g007

Elevated in highly lymphangiogenic IBC tumors compared to non-IBC cancers [12] and similarly in the ALDH-positive SUM-149 IBC stem-like cells. ALDH-positive stem cells have been reported to promote angiogenesis [49] and our observation of increased VEGF-D expression are consistent with a role in lymphangiogenesis. EGCG reduced the total levels VEGF-D mRNA and VEGF-D protein in tumors derived from ALDH-positive SUM-149 cells, which likely contributed to the decreased lymphatic vessel recruitment at the tumor periphery.

The ability of EGCG to repress a wider array of factors and have more profound phenotypic effects on SUM-149 cells compared to SUM-190 cells may be a result of differences in molecular subtypes, cellular heterogeneity or intrinsic signaling pathways between the two IBC tumors from which they were derived. SUM-149 cells have a triple negative hormone receptor status and are more highly proliferative compared to SUM-190 cells, which are ER-, PR- and Her-2 amplified. Importantly, the triple-negative subtype of IBC has been associated with decreased overall survival and increased rate of locoregional relapse [50]. Thus, our results showing more profound effects on the SUM-149 cell line, suggest the use of EGCG in combination with standard treatments for the triple-negative subtype of IBC may be particularly effective.

Conclusions

Here, we demonstrate for the first time that the green tea polyphenol EGCG has multiple inhibitory effects on highly malignant IBC cells. EGCG treatment in culture reduces IBC cell proliferation, invasive phenotype and ability to promote lymphangiogenesis at low doses and survival at higher doses. Notably, EGCG decreases growth and lymphangiogenic potential of pre-existing tumors derived from ALDH-positive stem-like cells, which have been associated with poor prognosis of IBC patients.

Supporting Information

Figure S1 VEGF-D antibody used in immunodepletion experiments fails to recognize VEGF-A or VEGF-C. Conditioned concentrated medium from untreated SUM-149 or SUM-190 cells was immunodepleted using a rabbit anti-VEGF-D antibody (sc-25784) (α-VD) or control normal rabbit IgG (sc-2027) (Ctrl), both purchased from Santa Cruz Biotechnology. Immunodepleted media were used in Western blot analysis with mouse monoclonal antibodies VEGF-A (MAB293) and VEGF-C (MAB752) [R&D Systems]. Alternatively, the media were assessed for VEGF-D (Fig. 5B). For each cell line, a representative of two independent experiments is shown. Values given below are averages relative to control sample set to 1 ± SE from two independent experiments, except for VEGF-D in SUM-149 cells, which is from a single experiment as VEGF-A was below detectable levels in the repeat experiment.

Materials S1 Reverse transcription (RT)-PCR conditions and primer sets.

(DOC)

Acknowledgments

We thank Stephen Ethier, Michael Pepper and Todd Reinhart for generously providing cell lines, Allen Parmelee and Mathilde Romagnoli for help with flow cytometry and Jack Erban for comments on the manuscript.

Author Contributions

Conceived and designed the experiments: NDM KEP ASY GES. Performed the experiments: NDM KEP. Analyzed the data: NDM KEP SPN ASY GES. Wrote the paper: NDM KEP SPN ASY GES.

References

1. Merajver SD, Sabel MS (2004) Inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins. 971 p.

2. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22: 9-23.

3. Cariti M, Bennett-Britton TM, Pinder SE, Purushotham AD (2005) “Inflammatory” breast cancer. Surg Oncol 14: 133–143.

4. Kleer CG, van Golken KL, Merajver SD (2000) Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423–429.

5. Lerebours F, Bieche I, Lidegaard R (2005) Update on inflammatory breast cancer. Breast Cancer Res 7: 52–58.

6. Vermeulen PB, van Golken KL, Dein LY (2010) Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 116: 2748-2754.

7. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, et al. (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110: 1436–1444.

8. Kleer CG, van Golken KL, Braun T, Merajver SD (2003) Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 16: 450–464.

9. Tomlinson JS, Alpaugh ML, Barsky SH (2001) An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 61: 5231–5241.

10. van Golken KL, Davies S, Wu ZF, Wang Y, Bucana CD, et al. (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC [lost in inflammatory breast cancer], and Rhof GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5: 2511–2519.

11. van Golken KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60: 5832–5838.

12. Van der Auwer A, Van Laere S, Van den Eynden GG, Benoy I, van Dam P, et al. (2004) Decreased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10: 7965-7971.

13. Skobe M, Hawighorst J, Jackson DG, Prevo R, Jenes L, et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198.

14. Stacker SA, Casasar C, Baldwin ME, Thornton GE, Williams RA, et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186–191.

15. Ginestier C, Hor MH, Charaf-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555–567.

16. Charaf-Jauffret E, Ginestier C, Livoin F, Tarpin C, Diebel M, et al. (2010) Aldh1l1-dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16: 45–55.

17. Haenszel W, Kurihara M (1968) Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43-68.

18. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, et al. (1993) Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 85: 1819–1827.

19. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, et al. (1998) Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89: 254–261.
20. Inoue M, Tajima K, Mizutani M, Iwata H, Iwase T, et al. (2001) Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett 167: 175–182.

21. Yang CS, Wang X (2010) Green tea and cancer prevention. Nutr Cancer 62: 931–937.

22. Forrozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, et al. (1999) Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81: 1320–1334.

23. Nisato M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in breast cancer cell invasion. Cancer Metastasis Rev 28: 261–271.

24. Minerva ND, Wang X, Yang S, Ying H, Xiao ZX, et al. (2009) Green tea polyphenols reverse cooperation between ER-α and CK2 that induces the aryl hydrocarbon receptor, shaggy, and an invasive phenotype. Cancer Res 69: 11742–11750.

25. Yang CS, Wang X (2010) Green tea and cancer prevention. Nutr Cancer 62: 1320–1334.

26. Belguise K, Guo S, Rogers AE, Seldin DC, et al. (2007) Green tea polyphenols reverse cooperation between ER-α and CK2 that induces the aryl hydrocarbon receptor, shaggy, and an invasive phenotype. Cancer Res 69: 11742–11750.

27. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, et al. (2007) Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9: 470–478.

28. Kim HJ, Chung H, Yoo YG, Kim H, Lee JY, et al. (2007) Inhibitor of DNA binding I activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-lalphal. Mol Cancer Res 5: 321–329.

29. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, et al. (2009) The hydroxylase pro-peptide attenuates fibroblastin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 284: 1383–1393.

30. Penny CA, Lee GY, Myers CA, Neve RM, Semenov J, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84–96.

31. Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154–165.

32. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302–1313.

33. Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, et al. (2013) Curcumin and curcuminoids inhibit cancer cell proliferation and induce apoptosis through modulation of pro-survival and pro-apoptotic signaling pathways in breast cancer cells. Cancer Lett 331: 1–9.

34. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, et al. (1999) WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21: 3172–3180.

35. McLaughlin J, Bigelow RL, Smith M, Elshajaj A, Anker M, et al. (2009) Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2: 675–682.

36. Bettiuzzi S, Brauni M, Rizzi F, Castagnetti G, Peracchia G, et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234–1240.

37. Brauni M, Rizzi F, Bettuzzi S (2008) Chemoprevention of human prostate cancer by green tea catechins: two years later: A follow-up update. Eur Urol 54: 472–473.

38. Shaufeld TD, Call TG, Zent CS, LaPlant B, Bowen DA, et al. (2009) Phase I trial of daily oral Polyphenol E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27: 3008–3014.

39. Ahn WS, You J, Huh SW, Kim CK, Lee JM, et al. (2005) Protective effects of green tea extracts (polyphenol E and EGCG) on human cervical lesions. Eur J Cancer Prev 12: 383–390.

40. Ma L, Allan AO (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292–306.

41. Morimoto K, Kim SJ, Tanoe T, Shimazu K, Tanji Y, et al. (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100: 1062–1068.

42. Tanoe T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15: 4234–4241.

43. Choudhary S, Sood S, Donnell RL, Wang HC (2012) Intervention of human breast cancer cell lines with long-term follow-up. Clin Cancer Res 9: 716–721.

44. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, et al. (2005) Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 11: 7637–7642.

45. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, et al. (2005) Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 11: 7637–7642.

46. Koch M, Detoni D, Van Nuffelen A, Souffreau J, Marconcini L, et al. (2009) VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J Pathol 219: 356–364.

47. Gu Y, Qi X, Guo S (2008) Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis 25: 717–725.

48. Nakamura Y, Yasuo H, Tsujimoto M, Yang Q, Imabun S, et al. (2003) Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res 9: 716–721.

49. Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Holm SA, et al. (2009) Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 113: 3340–3351.

50. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, et al. (2011) Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16: 1675–1683.